Study focuses on SARS-CoV-2 antibody seroprevalence in Wuhan and COVID-19 controls

Since the emergence in December 2019 in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide via transmission among close human contacts. Early on, several public health interventions were implemented in Wuhan city and Hubei Province, including lockdowns, social distancing, traffic restrictions, stay-at-home policies, face mask requirements, building temporary hospitals, and centralized quarantine. There were 50,355 confirmed cases of SARS-CoV-2 infection in Wuhan as of 28 January 2021.

According to a modeling study, the travel restrictions in Wuhan delayed the progression of the epidemic by 3 to 5 days in mainland China. They decreased international importations of SARS-CoV-2  by 80% through mid-February. The multifaceted public health interventions were associated with increased control of the COVID-19 outbreak in Wuhan city.

The study also showed that measures such as social distancing reduced transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and mitigated COVID-19 burden in Singapore and China. However, the study determined COVID-19 cases based on the detection of SARS-CoV-2 RNA in symptomatic patients and ignored large numbers of recovered symptomatic patients who did not get tested and asymptomatic patients.

Determining the cumulative incidence of SARS-CoV-2 infection in Wuhan using serologic tests

Researchers from China recently conducted serologic tests on 35,326 individuals to assess the cumulative incidence of SARS-CoV-2 infection in Wuhan city. The individuals in the study belonged to 4 different communities. The study is published in mSphere, an open-access journal published by the American Society for Microbiology.

The study results showed that 1,332 individuals (3.77%) tested positive for COVID-19 antibody – either Immunoglobulin M (IgM) or Immunoglobulin G (IgG). Males were found to have a lower positivity rate compared to females (3.02% vs. 4.52%). There was a clear increasing trend in antibody positivity rates based on patients’ ages and positivity varied across different communities. The findings indicate that public health measures may play a significant role in controlling SARS-CoV-2 transmission.

“Of note, the overall positive rate in Wuhan is lower than what was reported in other regions, like Spain (3.77% versus 5.0% to ∼6.2%) and Geneva, Switzerland (3.77% versus 10.8%).”

Study shows asymptomatic patients can have a greater risk of virus transmission than symptomatic patients

This study revealed that there is a higher prevalence rate of SARS-CoV-2 antibodies in the elderly population. Older adults are more likely to have comorbid conditions that may increase the severity of COVID-19 disease. Since asymptomatic patients do not have clinical symptoms, diagnosis and treatment can be delayed, and they may have a greater risk of virus transmission compared to symptomatic patients. This poses a massive challenge to infection control.

SARS-CoV-2 antibody seroprevalence in Wuhan, China. (A and B) Numbers (black bars) and proportions (gray bars) of COVID-19 antibody-positive (IgG or IgM) individuals divided by gender (A) or age (B). (C) COVID-19 antibody seroprevalence (colored bars) and detected cases (red line) in this study at different periods of time. Error bars represent 95% confidence intervals (95% CI). IgG1, positivity for IgG; IgM1, positivity for IgM; IgG1& IgM1, positivity for both IgG and IgM; IgG1/IgM1, positivity for either IgG or IgM.
SARS-CoV-2 antibody seroprevalence in Wuhan, China. (A and B) Numbers (black bars) and proportions (gray bars) of COVID-19 antibody-positive (IgG or IgM) individuals divided by gender (A) or age (B). (C) COVID-19 antibody seroprevalence (colored bars) and detected cases (red line) in this study at different periods of time. Error bars represent 95% confidence intervals (95% CI). IgG1, positivity for IgG; IgM1, positivity for IgM; IgG1& IgM1, positivity for both IgG and IgM; IgG1/IgM1, positivity for either IgG or IgM.

Reported cases in Wuhan were lesser than the actual infections due to asymptomatic COVID-19 infections

The findings of this study offer important data for the assessment of the status of the COVID-19 epidemic in the initial epicenter of Wuhan, China. About 3.77% of Wuhan’s population had detectable antibodies against the SARS-CoV-2 virus at the end of the first wave of the COVID-19 pandemic. According to the study results, the number of reported cases was lesser than the actual number of infections, likely due to many asymptomatic COVID-19 infections.

“Our detection of a relatively high proportion of IgM-positive individuals at a time when only 7 cases were confirmed by reverse transcription-PCR (RT-PCR) testing may suggest that asymptomatic virus transmission was continuing, undetected, in these communities.”

The results show that the widely used symptom-based screening strategy is insufficient to detect a significant percentage of potentially infectious COVID-19 cases and control the transmission of the virus. The authors mentioned that, although it is costly and time-consuming, a “pooled testing” strategy that tests all residents could be considered to screen several residents at once.

“Beyond the current phase of the pandemic, it may be necessary to proceed with a cautious approach in reopening businesses in areas of epidemicity to prevent potential future waves of COVID-19.”

Journal reference:
  • SARS-CoV-2 Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020 Huan Han, Junzhu Yi, Gongbo Cheng, Wuhui Jiang, Grzegorz M. Brożek, Yingan Jiang, Chengliang Zhu, Yuchen Xia mSphere Apr 2021, 6 (2) e01062-20; DOI: 10.1128/mSphere.01062-20, https://msphere.asm.org/content/6/2/e01062-20
Susha Cheriyedath

Written by

Susha Cheriyedath

Susha is a scientific communication professional holding a Master's degree in Biochemistry, with expertise in Microbiology, Physiology, Biotechnology, and Nutrition. After a two-year tenure as a lecturer from 2000 to 2002, where she mentored undergraduates studying Biochemistry, she transitioned into editorial roles within scientific publishing. She has accumulated nearly two decades of experience in medical communication, assuming diverse roles in research, writing, editing, and editorial management.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cheriyedath, Susha. (2021, April 25). Study focuses on SARS-CoV-2 antibody seroprevalence in Wuhan and COVID-19 controls. News-Medical. Retrieved on December 26, 2024 from https://www.news-medical.net/news/20210425/Study-focuses-on-SARS-CoV-2-antibody-seroprevalence-in-Wuhan-and-COVID-19-controls.aspx.

  • MLA

    Cheriyedath, Susha. "Study focuses on SARS-CoV-2 antibody seroprevalence in Wuhan and COVID-19 controls". News-Medical. 26 December 2024. <https://www.news-medical.net/news/20210425/Study-focuses-on-SARS-CoV-2-antibody-seroprevalence-in-Wuhan-and-COVID-19-controls.aspx>.

  • Chicago

    Cheriyedath, Susha. "Study focuses on SARS-CoV-2 antibody seroprevalence in Wuhan and COVID-19 controls". News-Medical. https://www.news-medical.net/news/20210425/Study-focuses-on-SARS-CoV-2-antibody-seroprevalence-in-Wuhan-and-COVID-19-controls.aspx. (accessed December 26, 2024).

  • Harvard

    Cheriyedath, Susha. 2021. Study focuses on SARS-CoV-2 antibody seroprevalence in Wuhan and COVID-19 controls. News-Medical, viewed 26 December 2024, https://www.news-medical.net/news/20210425/Study-focuses-on-SARS-CoV-2-antibody-seroprevalence-in-Wuhan-and-COVID-19-controls.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study reveals long-term brainstem damage in COVID-19 survivors using advanced MRI scans